Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Fluzone Quadrivalent

Sanofi reception

Sanofi takeover bid rebuffed by Medivation

Had sought to boost its portfolio by acquiring the US cancer therapies firm

- PMLiVE

Pfizer’s PCSK9 inhibitor clears another phase III trial

Bococizumab will compete with Praluent and Repatha if it reaches the market

- PMLiVE

Sanofi appoints Dr Yong-Jun Liu as head of research

He brings experience from MedImmune and the Baylor Research Institute

- PMLiVE

Dr Ameet Nathwani moves from Novartis to Sanofi

He becomes executive vice president, group chief medical officer

Sanofi appoints Diane Souza and Thomas Südhof

They join the board as independent directors

Sanofi reception

Sanofi bets on DiCE to find oral alternatives to injectable drugs

Makes the US biotech's discovery engine a core part of its R&D portfolio

- PMLiVE

First round to Amgen in PCSK9 patent battle with Sanofi

US court concludes Praluent has infringed rival cholesterol drug Repatha

Sanofi reception

Sanofi’s sarilumab beats Humira in head-to-head trial

Rheumatoid arthritis candidate was more effective than AbbVie's market-leader

- PMLiVE

Sanofi and Merck & Co dissolve longstanding vaccines alliance

Lacklustre sales at Sanofi Pasteur MSD prompts split

- PMLiVE

Lantus sales decline as competition heats up at Sanofi

Brand affected by biosimilars, growth of other new drugs and pricing pressure

dengue fever mosquito

EMA creates Zika virus task force

Will aid research and development of vaccines and medicines

National Institute for Health and Care Excellence NICE logo

NICE backs Repatha but rejects cholesterol rival Praluent

New draft guidance marks a U-turn on Amgen's drug but knocks back Sanofi treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links